Menthol smokers: Metabolomic profiling and smoking behavior

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 1, 2017, Pages 51-60

  Hsu, Ping Ching ^a,b   Lan, Renny S ^a   Brasky, Theodore M ^a   Marian, Catalin ^a,c   Cheema, Amrita K ^d   Ressom, Habtom W ^d   Loffredo, Christopher A ^d   Pickworth, Wallace B ^e   Shields, Peter G ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d GEORGETOWN UNIVERSITY   (United States)

^e BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BENZENE; BILIRUBIN; CARBON MONOXIDE; COTININE; GLYCEROPHOSPHOLIPID; INDOLE DERIVATIVE; MENTHOL; NICOTINE; SULFURIC ACID; TRYPTOPHAN; URIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CELL DEATH; CELL MOTION; CELL SURVIVAL; CROSS-SECTIONAL STUDY; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; HUMAN; METABOLOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SMOKING; AGE; BLOOD; CIGARETTE SMOKING; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGY; REPRODUCIBILITY; RISK ASSESSMENT; SEX FACTOR;

ADULT; AGE FACTORS; BIOMARKERS; CIGARETTE SMOKING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTHOL; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEX FACTORS; SMOKING;

EID: 85009085867     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0124     Document Type: Article

References (78)

1. Tobacco Products Scientific Advisory Committee. Menthol cigarettes and public health: review of the scientific evidence and recommendations. Silver Spring, MD: U.S. Food and Drug Administration; 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/tobaccoproductsscientificadvisorycommittee/ucm269697.pdf.
2. Lawrence D, Cadman B, Hoffman AC. Sensory properties of menthol and smoking topography. Tob Induc Dis 2011;9(Suppl 1):S3.
3. U.S. Food and Drug Administration. Preliminary scientific evaluation of the possible public health effects ofmenthol versus nonmenthol cigarettes. Silver Spring, MD: U.S. Food and Drug Administration; 2013. Available from:http://www.fda.gov/downloads/UCM361598.pdf.
4. U.S. Food and Drug Administration. FDA invites public input on menthol in cigarettes. Silver Spring, MD: U.S. Food and Drug Administration; 2013.
5. Gardiner PS. The African Americanization of menthol cigarette use in the United States. Nicotine Tob Res 2004;6Suppl 1:S55-S65.
6. Celebucki CC, Wayne GF, Connolly GN, Pankow JF, Chang EI. Characterization of measured menthol in 48 U.S. cigarette sub-brands. Nicotine Tob Res 2005;7:523-31.
7. Kreslake JM, Wayne GF, Alpert HR, Koh HK, Connolly GN. Tobacco industry control of menthol in cigarettes and targeting of adolescents and young adults. Am J Public Health 2008;98:1685-92.
8. Anderson SJ. Marketing of menthol cigarettes and consumer perceptions: A review of tobacco industry documents. Tob Control 2011;20Suppl 2: ii20-8.
9. Klausner K. Menthol cigarettes and smoking initiation: A tobacco industry perspective. Tob Control 2011;20Suppl 2:ii12-9.
10. Yerger VB. Menthol's potential effects on nicotine dependence: A tobacco industry perspective. Tob Control 2011;20Suppl 2:ii29-36.
11. Jones MR, Tellez-Plaza M, Navas-Acien A. Smoking, menthol cigarettes and all-cause, cancer and cardiovascularmortality: evidence from the National Health and Nutrition Examination Survey(NHANES) and ameta-Analysis. PLoS One 2013;8:e77941.
12. Duner-EngstromM, Larsson O, Lundberg J, Fredholm BB. Effect of nicotine chewing gum on salivary secretion. Swed Dent J 1986;10:93-6.
13. Sloan A, De Cort SC, Eccles R. Prolongation of breath-hold time following treatment with an L-menthol lozenge in healthy man. J Physiol 1993; 473:53P.
14. Squier CA, Mantz MJ, Wertz PW. Effect of menthol on the penetration of tobacco carcinogens and nicotine across porcine oral mucosa ex vivo. Nicotine Tob Res 2010;12:763-7.
15. Benowitz NL, Herrera B, Jacob P III. Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther 2004;310:1208-15.
16. Muscat JE, Chen G, Knipe A, Stellman SD, Lazarus P, Richie JP Jr. Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation. Cancer Epidemiol Biomarkers Prev 2009;18:35-41.
17. Brinkman MC, Chuang JC, Gordon SM, Kim H, Kroeger RR, Polzin GM, et al. Exposure to and deposition of fine and ultrafine particles in smokers of menthol and nonmenthol cigarettes. Inhal Toxicol 2012;24:255-69.
18. Yerger VB, McCandless PM. Menthol sensory qualities and smoking topography: A review of tobacco industry documents. Tob Control 2011; 20Suppl 2:ii37-43.
19. Sidney S, Tekawa IS, Friedman GD, Sadler MC, Tashkin DP. Mentholated cigarette use and lung cancer. Arch Intern Med 1995;155:727-32.
20. Carpenter CL, Jarvik ME, Morgenstern H, McCarthy WJ, London SJ. Mentholated cigarette smoking and lung-cancer risk. Ann Epidemiol 1999; 9:114-20.
21. Kabat GC, Hebert JR. Use of mentholated cigarettes and oropharyngeal cancer. Epidemiology 1994;5:183-8.
22. Hebert JR, Kabat GC. Menthol cigarette smoking and oesophageal cancer. Int J Epidemiol 1989;18:37-44.
23. Hsu PC, Lan RS, Brasky TM, Marian C, Cheema AK, Ressom HW, et al. Metabolomic profiles of current cigarette smokers. Mol Carcinog. 2016 Jun
24. [Epub ahead of print].
25. Benowitz NL, Zevin S, Jacob P III. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 1998;287:958-62.
26. Perez-Stable EJ, Herrera B, Jacob P III, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998;280:152-6.
27. Tautenhahn R, Patti GJ, Rinehart D, Siuzdak G. XCMS Online: A web-based platform to process untargeted metabolomic data. Anal Chem 2012;84: 5035-9.
28. Perez-Stable EJ, Benowitz NL, Marin G. Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med 1995;24:171-9.
29. Giovino GA, Sidney S, Gfroerer JC, O'Malley PM, Allen JA, Richter PA, et al. Epidemiology of menthol cigarette use. Nicotine Tob Res 2004;6Suppl 1: S67-81.
30. Cubbin C, Soobader MJ, LeClere FB. The intersection of gender and race/ethnicity in smoking behaviors amongmenthol and non-menthol smokers in the United States. Addiction 2010;105Suppl 1:32-8.
31. Gust SW, Pickens RW, Pechacek TF. Relation of puff volume to other topographical measures of smoking. Addict Behav 1983;8:115-9.
32. Epstein LH, Dickson BE, Ossip DJ, Stiller R, Russell PO, Winter K. Relationships among measures of smoking topography. Addict Behav 1982;7: 307-10.
33. Marian C, O'Connor RJ, Djordjevic MV, Rees VW, Hatsukami DK, Shields PG. Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. Cancer Epidemiol Biomarkers Prev 2009;18:3305-20.
34. Perkins KA, Karelitz JL, Giedgowd GE, Conklin CA. The reliability of puff topography and subjective responses during ad lib smoking of a single cigarette. Nicotine Tob Res 2012;14:490-4.
35. Ahijevych K, Parsley LA. Smoke constituent exposure and stage of change in black and white women cigarette smokers. Addict Behav 1999;24:115-20.
36. Jarvik ME, Tashkin DP, Caskey NH, McCarthy WJ, Rosenblatt MR. Mentholated cigarettes decrease puff volume of smoke and increase carbon monoxide absorption. Physiol Behav 1994;56:563-70.
37. McCarthy WJ, Caskey NH, Jarvik ME, Gross TM, Rosenblatt MR, Carpenter C. Menthol vs. nonmenthol cigarettes: effects on smoking behavior. Am J Public Health 1995;85:67-72.
38. Nil R, Battig K. Separate effects of cigarette smoke yield and smoke taste on smoking behavior. Psychopharmacology 1989;99:54-9.
39. Ahijevych K, Gillespie J, Demirci M, Jagadeesh J. Menthol and nonmenthol cigarettes and smoke exposure in black and white women. Pharmacol Biochem Behav 1996;53:355-60.
40. Miller GE, Jarvik ME, Caskey NH, Segerstrom SC, Rosenblatt MR, McCarthy WJ. Cigarette mentholation increases smokers' exhaled carbon monoxide levels. Exp Clin Psychopharmacol 1994;2:154-60.
41. Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend 2007;86: 294-300.
42. Strasser AA, Ashare RL, Kaufman M, Tang KZ, Mesaros AC, Blair IA. The effect of menthol on cigarette smoking behaviors, biomarkers and subjective responses. Cancer Epidemiol Biomarkers Prev 2013;22:382-9.
43. Caskey NH, Jarvik ME, McCarthyWJ, Rosenblatt MR, Gross TM, Carpenter CL. Rapid smoking of menthol and nonmenthol cigarettes by black and white smokers. Pharmacol Biochem Behav 1993;46:259-63.
44. Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, et al. Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev 2003;12:468-71.
45. Clark PI, Gautam S, Gerson LW. Effect of menthol cigarettes on biochemical markers of smoke exposure among black and white smokers. Chest 1996;110:1194-8.
46. Pickworth WB, Moolchan ET, Berlin I, Murty R. Sensory and physiologic effects of menthol and non-menthol cigarettes with differing nicotine delivery. Pharmacol Biochem Behav 2002;71:55-61.
47. Heck JD. A review and assessment of menthol employed as a cigarette flavoring ingredient. Food Chem Toxicol 2010;48Suppl 2:S1-S38.
48. Ahijevych K, Garrett BE. Menthol pharmacology and its potential impact on cigarette smoking behavior. Nicotine Tob Res 2004;6Suppl 1:S17-S28.
49. Ferris Wayne G, Connolly GN. Application, function, and effects of menthol in cigarettes: A survey of tobacco industry documents. Nicotine Tob Res 2004;6Suppl 1:S43-S54.
50. Gelal A, Jacob P III, Yu L, Benowitz NL. Disposition kinetics and effects of menthol. Clin Pharmacol Ther 1999;66:128-35.
51. Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P III. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev 2010;19:3013-9.
52. Spichiger M, Muhlbauer RC, Brenneisen R. Determination of menthol in plasma and urine of rats and humans by headspace solid phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2004;799:111-7.
53. Hiki N, Kaminishi M, Hasunuma T, Nakamura M, Nomura S, Yahagi N, et al. A phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of L-menthol in upper gastrointestinal endoscopy. Clin Pharmacol Ther 2011;90:221-8.
54. Muller DC, Degen C, Scherer G, Jahreis G, Niessner R, Scherer M. Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILICMS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. J Chromatogr B Anal Technol Biomed Life Sci 2014;966:117-26.
55. Wang-Sattler R, Yu Y, Mittelstrass K, Lattka E, Altmaier E, Gieger C, et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-first results from the KORA study. PLoS One 2008;3: e3863.
56. Xu T, Holzapfel C, Dong X, Bader E, Yu Z, Prehn C, et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med 2013;11:60.
57. Bernhardt G, Biersack B, Bollwein S, Schobert R, Zoldakova M. Terpene conjugates of diaminedichloridoplatinum(II) complexes: Antiproliferative effects in HL-60 leukemia, 518A2 melanoma, and HT-29 colon cancer cells. Chem Biodivers 2008;5:1645-59.
58. Kim SH, Nam JH, Park EJ, Kim BJ, Kim SJ, So I, et al. Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. Biochim Biophys Acta 2009;1792:33-8.
59. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002;72:247-55.
60. Seo KA, Kim H, Ku HY, Ahn HJ, Park SJ, Bae SK, et al. The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chem Biol Interact 2008;174:141-6.
61. Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman JR. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. JMed Chem 2006;49:6987-7001.
62. Munder PG, Modolell M, Andreesen R, Weltzien HU, Westphal O. Lysophosphatidylcholine (lysolecithin) and its synthetic analogues. Immunemodulating and other biologic effects. Springer Semin Immunopathol 1979;2:187-203.
63. Mehta D. Lysophosphatidylcholine: An enigmatic lysolipid. Am J Physiol Lung Cell Mol Physiol 2005;289:L174-5.
64. Haley JE, Stefano GB, Catapane EJ. Correlation between acidic phospholipids and serotonin and between lysolecithin and dopamine in ganglia of the marine mussel, Mytilus edulis. Experientia 1978;34:210-2.
65. Ryborg AK, Johansen C, Iversen L, Kragballe K. Lysophosphatidylcholine induces keratinocyte differentiation and upregulation of AP-1-And NFkappaB DNA-binding activity. Acta Derm Venereol 2004;84:433-8.
66. Perrin-Cocon L, Agaugue S, Coutant F, Saint-Mezard P, Guironnet-Paquet A, Nicolas JF, et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 2006;24:1254-63.
67. Aiyar N, Disa J, Ao Z, Ju H, Nerurkar S, Willette RN, et al. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 2007;295:113-20.
68. Rikitake Y, Kawashima S, Yamashita T, Ueyama T, Ishido S, Hotta H, et al. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler Thromb Vasc Biol 2000;20:1006-12.
69. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, et al. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994;269:31430-5.
70. Gillett MP, Besterman EM. Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic diseases. Atherosclerosis 1975;22:111-24.
71. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 2003;44:754-61.
72. Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 2011;50:313-30.
73. Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: Their metabolism, incorporation intomembranes, functions, and involvement in neurological disorders. Chem Phys Lipids 2000;106:1-29.
74. Kwatia MA, Doyle CB, Cho W, Enhorning G, Ackerman SJ. Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis. J Allergy Clin Immunol 2007;119:838-47.
75. Andersson DA, NashM, Bevan S.Modulation of the cold-Activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. J Neurosci 2007;27:3347-55.
76. Gentry C, Stoakley N, Andersson DA, Bevan S. The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity. Mol Pain 2010;6:4.
77. Canales L, Chen J, Kelty E, Musah S, Webb C, Pisano MM, et al. Developmental cigarette smoke exposure: liver proteome profile alterations in low birth weight pups. Toxicology 2012;300:1-11.
78. Weng DY, Chen J, Taslim C, Hsu PC, Marian C, David SP, et al. Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog 2016;55:1424-37.